NVENTA ANNOUNCES POSITIVE HSPE7 DATA

A A

Nventa Biopharmaceuticals has announced results, recently published in the journal AIDS, from a clinical trial to test HspE7, an investigational therapeutic vaccine for human papillomavirus (HPV)-related diseases, on patients with high-grade anal intraepithelial neoplasia (AIN), or dysplasia, in HIV-positive individuals.

The Phase I/II trial tested HspE7 in three cohorts of five participants each assigned to receive variable doses of HspE7 through three injections at four-week intervals. Anal disease was assessed by pathology at 8, 12, 24 and 48 weeks, and 39 different types of HPV were measured, including types 16, 18 and 31. At 48 weeks, five of the fifteen participants in the trial (33 percent) responded to HspE7 and regressed to low-grade anal or no significant dysplasia. All participants had at least one oncogenic HPV type at
baseline.